STRENGTHENING DERMATOLOGICAL THERAPY ACCESS IN POLAND
TOOsonix, renowned for its pioneering work in dermatological therapy devices, has initiated a strategic partnership with Consultronix. This collaboration is poised to enhance the treatment landscape for skin diseases in Poland, where more than 37 million individuals reside. The focused ultrasound technology developed by TOOsonix offers innovative solutions to address various skin conditions effectively.
INTRODUCING CUTTING-EDGE SOLUTIONS
The partnership aims to introduce TOOsonix's advanced focused ultrasound skin therapy to healthcare professionals in Poland, significantly improving the accessibility of treatment options for patients. This technology is groundbreaking in treating age-related skin diseases, including conditions such as basal cell carcinoma, actinic keratosis, and seborrheic keratosis.
A NON-INVASIVE APPROACH
The therapy provided by TOOsonix's MDR CE-marked system is characterized by its non-invasive nature, facilitating quick treatments without the need for anesthesia or post-procedure downtime. Patients can expect not only faster treatment sessions but also improved aesthetic outcomes compared to conventional methods.
ADDRESSING THE NEEDS OF AN AGING POPULATION
In Poland, approximately 20% of the population is aged 65 and over, indicating a rising prevalence of skin diseases within a significant demographic. The partnership aims to enhance the quality of care and treatment options available to this group, addressing an essential healthcare need.
COLLABORATIVE EFFORT TOWARD INNOVATION
The founders of TOOsonix, Torsten Bove and Tomasz Zawada, expressed their excitement regarding this partnership: "Working with Consultronix allows us to expand our influence in Central Europe. Their extensive knowledge of the Polish market and unwavering commitment to quality make them the perfect collaborator. Together, we hope to implement transformative dermatological solutions that can significantly enhance patient care."
THE ROLE OF CONSULTRONIX
Consultronix, recognized for its capabilities in the Polish medical device market, plays a critical role in this collaboration. With over 38 years of experience, the company has built solid relationships with dermatology clinics and hospitals, ensuring a smooth rollout of TOOsonix’s innovative products.
COMMITMENT TO PATIENT OUTCOMES
According to Piotr Smolarski, CEO of Consultronix, the company sees this partnership as an opportunity to align its mission with TOOsonix's vision for advancing healthcare: "We are thrilled to work alongside TOOsonix and are committed to providing Polish healthcare professionals with exceptional tools to meet the evolving demands of patient care."
A MILESTONE IN INTERNATIONAL EXPANSION
This strategic alliance signifies a meaningful step in TOOsonix's international expansion strategy, reinforcing its ambition to bring cutting-edge dermatological therapies to a broader audience in Europe. The company continues to work collaboratively with healthcare providers, ensuring the delivery of safe and effective solutions.
ABOUT TOOsonix
TOOsonix specializes in high-intensity focused ultrasound technology aimed at treating a range of skin conditions, both cancerous and non-cancerous. Their commitment to innovation places them at the forefront of dermatological healthcare solutions across Europe and the U.S.
ABOUT CONSULTRONIX
For over three decades, Consultronix has established itself as a premier distributor of medical devices within Poland, focusing on delivering cutting-edge technologies and fostering patient satisfaction.
CONTACT INFORMATION
For media inquiries, please contact:
Torsten Bove
Managing Director
Phone: +45 2059 2999
FREQUENTLY ASKED QUESTIONS
What is the focus of the partnership between TOOsonix and Consultronix?
The partnership aims to introduce advanced dermatological therapies using focused ultrasound technology in Poland.
What kinds of skin conditions does TOOsonix address?
TOOsonix's technology is suitable for treating various skin diseases, including basal cell carcinoma and actinic keratosis.
How does the TOOsonix treatment differ from traditional methods?
TOOsonix's treatment is non-invasive, quicker, and requires no anesthesia or downtime, offering better aesthetic outcomes.
Why is this collaboration significant for Poland?
This partnership addresses the growing healthcare needs of an aging population in Poland, providing improved treatment options.
Where can I find more information about TOOsonix?
More details about TOOsonix's innovations can be found on their official website.
